Company Encyclopedia
View More
name
Pharming Group NV
PHAR.US
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105.
1.897 T
PHAR.USMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
B
BiotechnologyIndustry
Industry Ranking30/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.16%D
    • Profit Margin0.11%D
    • Gross Margin92.73%A
  • Growth ScoreA
    • Revenue YoY26.78%A
    • Net Profit YoY102.14%A
    • Total Assets YoY11.34%B
    • Net Assets YoY17.21%A
  • Cash ScoreA
    • Cash Flow Margin94836.13%A
    • OCF YoY26.78%A
  • Operating ScoreB
    • Turnover0.81B
  • Debt ScoreC
    • Gearing Ratio44.14%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pharming Group (ENXTAM:PHARM): Valuation Insights Following Raised 2025 Outlook and Strong Earnings Momentum

    Pharming Group (ENXTAM:PHARM) has raised its 2025 revenue outlook following strong earnings, with sales increasing and net loss narrowing. The stock has seen a 44.7% year-to-date return and a 98% total shareholder return over the past year. Trading at a P/S ratio of 3x, the stock appears undervalued compared to its biotech peers. However, potential risks include slower revenue growth and regulatory challenges. A DCF model suggests further upside potential, indicating the stock is trading below fair value.

    Simplywall·
    US
    PHAR
    +1.26%
    Simplywall·
    US
    PHAR
    +1.26%

    Pharming Group NV Publishes Transcript of Q3 2025 Financial Results Call

    Pharming Group NV has released the transcript of its Q3 2025 earnings call, highlighting a 30% year-over-year revenue growth and an operating profit of US$15.8 million. The company reported an operating cash flow of US$32 million, nearly restoring its cash position to pre-acquisition levels. Management discussed the rapid advancement of its product pipeline and announced leadership changes, including a new Chief Commercial Officer. The full transcript is available through the provided link.

    Reuters·
    US
    PHAR
    +1.26%
    Reuters·
    US
    PHAR
    +1.26%

    Pharming Group (OTCMKTS:PHGUF) Reaches New 52-Week High - Here's What Happened

    Pharming Group (OTCMKTS:PHGUF) reached a new 52-week high of $1.53 during trading, with a volume of 2,400 shares. The company reported a quarterly EPS of $0.01 and revenue of $97.30 million, exceeding analysts' expectations of $80.18 million. Pharming specializes in biopharmaceuticals for rare diseases, offering treatments like RUCONEST and Joenja. Despite a Hold rating from analysts, the stock's performance has drawn attention, although it was not included in a list of top stock recommendations.

    Market Beat·
    US
    PHAR
    +1.26%
    Market Beat·
    US
    PHAR
    +1.26%

    Pharming Group N.V. Reports Strong Q3 2025 Earnings

    Pharming Group N.V. reported strong Q3 2025 earnings, with a 30% revenue increase year-on-year, reaching an operating profit of $15.8 million. Key products RUCONEST and Joenja saw revenue growth of 29% and 35%, respectively. The company upgraded its full-year revenue guidance to $365-$375 million. Operating cash flow improved to $32 million, restoring its cash position. Despite plans to withdraw RUCONEST from certain markets, Pharming remains optimistic about future growth, supported by pipeline advancements and a gross margin improvement to 93%.

    Tip Ranks·
    US
    PHAR
    +1.26%
    Tip Ranks·
    US
    PHAR
    +1.26%

    DigitalOcean Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.

    benzinga_article·
    US
    DOCN
    +0.18%
    benzinga_article·
    US
    DOCN
    +0.18%